Silver Spring, Maryland–(ENEWSPF)–December 8, 2015. Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
FDA Approves First Drug to Treat a Rare Enzyme Disorder in Pediatric and Adult Patients
More in Health and Fitness:
